12.28.09
Synta Pharmaceuticals Corp. has initiated a Phase II trial of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).
“We and our collaborators have been encouraged by the strong preclinical results for STA-9090 in GIST as well as early results from our solid tumor Phase I trials, where STA-9090 has generated objective tumor responses and has been well-tolerated, with the most common adverse events, fatigue and gastrointestinal toxicities, being manageable and reversible,” said Vojo Vukovic, M.D., Ph.D., senior vice president and chief medical officer, Synta Pharmaceuticals. “A particularly encouraging observation was that a GIST patient on our once-weekly dosing Phase I solid tumor study, who experienced disease progression while on multiple prior therapies, including Gleevec and Sutent, experienced substantial tumor shrinkage and stabilization of disease following treatment with STA-9090. We are looking forward to working closely with leading GIST investigators to evaluate the potential of STA-9090 to benefit patients with this disease.”
Synta expects to report data from the ongoing Phase I and Phase 1/2 trials and initiate studies in other cancer indications in 1H10.
“We and our collaborators have been encouraged by the strong preclinical results for STA-9090 in GIST as well as early results from our solid tumor Phase I trials, where STA-9090 has generated objective tumor responses and has been well-tolerated, with the most common adverse events, fatigue and gastrointestinal toxicities, being manageable and reversible,” said Vojo Vukovic, M.D., Ph.D., senior vice president and chief medical officer, Synta Pharmaceuticals. “A particularly encouraging observation was that a GIST patient on our once-weekly dosing Phase I solid tumor study, who experienced disease progression while on multiple prior therapies, including Gleevec and Sutent, experienced substantial tumor shrinkage and stabilization of disease following treatment with STA-9090. We are looking forward to working closely with leading GIST investigators to evaluate the potential of STA-9090 to benefit patients with this disease.”
Synta expects to report data from the ongoing Phase I and Phase 1/2 trials and initiate studies in other cancer indications in 1H10.